Drugs / CLN-081
last change Dec 2025 re-read 2 minutes ago

CLN-081

also known as TAS6417 · Zipalertinib · TPC-064

Small molecule targets EGFR via inhibition

Developed for
non-small cell lung carcinoma
Investigated by
Taiho Oncology, Inc. · Cullinan Therapeutics Inc. · Jonsson Comprehensive Cancer Center

Trials 6 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/21 trial
Phase 1/2 NCT04036682 Oct 2019 → Oct 2025 overdue non-small cell lung carcinoma Cullinan Therapeutics Inc. Active not recruiting No outcome recorded
Phase 22 trials
Phase 2 NCT07229339 Jun 2027 → Jun 2029 expected non-small cell lung carcinoma Jonsson Comprehensive Cancer Center Not yet recruiting No outcome recorded
Phase 2 NCT05967689 Jul 2023 → Aug 2028 expected Taiho Oncology, Inc. Recruiting No outcome recorded
Phase 32 trials
Phase 3 NCT07128199 Dec 2025 → Oct 2029 expected non-small cell lung carcinoma Taiho Oncology, Inc. Active not recruiting No outcome recorded
Phase 3 NCT05973773 Dec 2023 → Oct 2026 expected Taiho Oncology, Inc. Active not recruiting No outcome recorded
Phase not stated1 trial
NCT07601399 non-small cell lung carcinoma Taiho Oncology, Inc. Available No outcome recorded

Evidence & citations 8 cited values

Every value below carries the sentence it was read from. 9 sources stand behind the page.

FieldValueCited text
Known as CLN-081 “TAS6417/ CLN-081NCT05967689
1

NCT04036682

Known as TAS6417 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07128199
2

NCT05967689

NCT05973773

Known as TPC-064 ChEMBL registry synonym — accepted as the source's own label CHEMBL4650281
Known as Zipalertinib ClinicalTrials.gov intervention name — accepted as the source's own label NCT07229339
1

NCT07601399

Action Inhibit “an irreversible epidermal growth factor receptor (EGFR) inhibitor” PMID 40450572 Jun 2025
Modality Small molecule CHEMBL4650281
Route Oral “dose levels including 30, 45, 65, 100, and 150 mg orally twice a day” PMID 37384848 Jun 2023
Target EGFR “oral EGFR tyrosine kinase inhibitor” PMID 37384848 Jun 2023